Analysts’ Recent Ratings Changes for Vectura Group (VEC)

Share on StockTwits

A number of research firms have changed their ratings and price targets for Vectura Group (LON: VEC):

  • 6/10/2019 – Vectura Group had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 6/10/2019 – Vectura Group had its “hold” rating reaffirmed by analysts at Peel Hunt.
  • 6/4/2019 – Vectura Group had its “hold” rating reaffirmed by analysts at Peel Hunt.
  • 5/24/2019 – Vectura Group had its “hold” rating reaffirmed by analysts at Peel Hunt. They now have a GBX 119 ($1.55) price target on the stock.
  • 5/24/2019 – Vectura Group had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 5/24/2019 – Vectura Group had its “buy” rating reaffirmed by analysts at Morgan Stanley. They now have a GBX 160 ($2.09) price target on the stock.
  • 5/24/2019 – Vectura Group had its “buy” rating reaffirmed by analysts at Numis Securities Ltd.
  • 5/9/2019 – Vectura Group had its price target raised by analysts at Peel Hunt from GBX 105 ($1.37) to GBX 119 ($1.55). They now have a “hold” rating on the stock.
  • 5/8/2019 – Vectura Group had its “hold” rating reaffirmed by analysts at Shore Capital.
  • 5/8/2019 – Vectura Group had its “buy” rating reaffirmed by analysts at Numis Securities Ltd. They now have a GBX 160 ($2.09) price target on the stock.
  • 5/2/2019 – Vectura Group had its “hold” rating reaffirmed by analysts at Peel Hunt.

VEC traded up GBX 0.40 ($0.01) during trading on Wednesday, hitting GBX 80.85 ($1.06). The company had a trading volume of 466,597 shares, compared to its average volume of 4,610,000. The stock has a market capitalization of $536.74 million and a P/E ratio of -6.13. Vectura Group PLC has a one year low of GBX 65.85 ($0.86) and a one year high of GBX 90.15 ($1.18). The company has a current ratio of 2.35, a quick ratio of 1.90 and a debt-to-equity ratio of 0.81.

Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.

See Also: Gap Down Stocks

Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts’ Recent Ratings Changes for Vectura Group
Analysts’ Recent Ratings Changes for Vectura Group
DeepBrain Chain  Price Up 4.1% This Week
DeepBrain Chain Price Up 4.1% This Week
$121.15 Million in Sales Expected for Del Taco Restaurants Inc  This Quarter
$121.15 Million in Sales Expected for Del Taco Restaurants Inc This Quarter
Tocagen  Sees Strong Trading Volume
Tocagen Sees Strong Trading Volume
Oxford Industries  Issues FY 2019 Earnings Guidance
Oxford Industries Issues FY 2019 Earnings Guidance
Dock  Trading Up 10% This Week
Dock Trading Up 10% This Week


© 2006-2019 Ticker Report